To Present at Austrade Mission on Regenmed in Japan
Sydney, Dec 7, 2015 AEST (ABN Newswire) - Regeneus Ltd (
ASX:RGS), a clinical-stage regenerative medicine company, announced today that John Martin, CEO, will present at Austrade's Mission on Regenerative Medicine Opportunities in Japan, on Monday 7 December in Tokyo and Wednesday 9 December in Kobe.
Organised by Austrade, the Australian government's export, international education and foreign investment promotion agency, this four-day mission is aimed to promote Australian regenerative medicine technologies and research capabilities and explore collaboration opportunities in Japan. The seminars will be co-hosted by the Forum for Regenerative Medicine (FIRM), the peak industry body in Japan.
The mission will hear from the newly formed Agency for Medical Research and Development (AMED) and the Ministry of Health, Labour and Welfare (MHLW).
Corporate members of FIRM, the Japan Bioindustry Association, companies located in the Kobe Biomedical Precinct, companies of Osaka Pharmaceutical Manufacturers Association as well as government officials and industrial and academic contacts, will attend the mission.
The market in Japan for regenerative medicines is projected to grow to US$12.7bn by 2030 according to the Japanese government. The development of the cell and tissue regeneration industry is one of the pillars of the Growth Strategy of the Abe Administration. In November 2014, Japan introduced new laws to enhance the development of the regenerative market including a significantly shorter approval process for commercialisation of new cell therapies.
Regeneus has targeted the Japanese market for its Progenza allogeneic stem cell therapy for osteoarthritis. The company plans to conduct a phase 2 trial for Progenza in Japan. The company has spent over 12 months in due diligence on the market opportunity and is focused on securing a Japanese manufacturing and clinical partner for Progenza in the near term.
This mission is being held against the backdrop of the commencement in January 2015 of the historic Japan-Australia Economic Partnership Agreement which has been designed to encourage business activity between Australia and its 2nd largest trading partner, Japan.
To view the presentation, please visit:
http://media.abnnewswire.net/media/en/docs/ASX-RGS-896179.pdf
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.
| ||
|
